Sanofi's R&D day poses some big challenges as skeptics circle in wake of a Dengvaxia fiasco
The view from John Carroll
Tomorrow the analysts that cover Sanofi $SNY will gather in Paris to hear the pharma giant outline its R&D strategy. And more than a few skeptics from the investor community will be on hand.
After relying on partners like Regeneron $REGN and Alnylam $ALNY to deliver the goods on innovation and significant new progress in drug development, chief scientist Elias Zerhouni believes it’s time to become more self-reliant.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.